Parmax Pharma Ltd. Announces Board Meeting to Discuss Preferential Fund Raising and Capital Raising Proposals
Parmax Pharma Ltd., a manufacturer of Bulk Drugs, Drug Intermediates, and Speciality Chemicals, has scheduled a Board meeting to evaluate significant proposals related to capital infusion and expansion strategies.The Board of Directors is set to meet on Monday, June 08, 2026. The meeting will take place at the company's registered office located in Rajkot, Gujarat.
The primary agenda items for the board include evaluating a proposal for raising funds through the issuance of eligible securities. This fundraising initiative could involve equity shares or any equity linked instruments via preferential issue or other methods determined appropriate by the Board. The meeting is also intended to approve necessary ancillary actions related to this fund raising in accordance with applicable laws and regulations.
Furthermore, the company plans to seek shareholder approval for these matters through an Extraordinary General Meeting (EGM). The board will be tasked with approving the draft notice and determining the date and venue for this EGM.
Trading Window Closure Announced
In line with insider trading protocols, Parmax Pharma Ltd. has declared that the trading window for dealing in the company's securities remains closed starting June 03, 2026. The restriction period will continue until 48 hours after the conclusion of the Board Meeting scheduled for June 08, 2026.All Directors, Connected Persons, Designated Persons, and their immediate relatives have been advised not to trade in the securities of Parmax Pharma Ltd. during this restricted period.
Stock Price Movement
Parmax Pharma Ltd shares settled at ₹44.49 on Wednesday, buoyed by a 9.39% gain in closing trade. The stock moved throughout the day within an intraday range spanning from a low of ₹37.00 to a high of ₹45.00.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.